[UKPRwire, Mon Nov 27 2017] The Latest Comprehensive Industry
research study titled, Diabetes Devices And Drugs Market by Products,
Application - Global Industry Analysis and Forecast To 2022 published by
Crystal Market Research. Diabetes occurs either when the pancreas does
not produce enough insulin or when the body cannot effectively use the
insulin. Symptoms associated with diabetes are frequent urination,
blurred vision, increased thirst, rapid weight loss, numbness or
tingling sensation in hands or feet and increased hunger. Factors which
increase the risk of diabetes are ethnicity, family history, unhealthy
diet, physical inactivity and smoking. Diabetes can damage the heart,
eyes, blood vessels, kidneys, and nerves which may lead to disability
and premature death. There are three types of diabetes, namely, type 1,
type 2 and gestational diabetes. Type 1 diabetes can cause due to
complex interaction between genes and environmental factors. The most
common risk factors for type 2 diabetes are overweight and obesity.
However, gestational diabetes develops only during pregnancy. Continuous
blood glucose monitoring devices continuously monitors the blood sugar
level and displays the data on the monitor. Flash glucose monitors are
also used to monitor blood glucose. The monitor shows reading only after
scanning its sensor. The insulin pump is a computerized device that
helps in controlling diabetes. This pump releases insulin through a
catheter into the body. The user can adjust the dose of insulin to be
delivered by this pump. Anti diabetic drugs are used for controlling
diabetes. These medicines help to control and stabilize the blood
glucose level. In patients with type 1 diabetes, insulin is used,
whereas in patients with type 2 diabetes, sulfonylurea, biguanides,
meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors,
alpha-glucosidase inhibitors, sodium glucose cotransporter 2 inhibitors
(SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used. In type 1
diabetes, the insulin used is created by growing insulin proteins within
E-coli bacteria in laboratory. The analog insulin is available into
various forms. One of the forms is long acting analog insulin. The long
acting analog insulin stays in the body for 24 hours, whereas the
intermediate acting analog insulin stays in the body for 16 to 24 hours.
Another form of insulin is rapid acting analog insulin. Rapid acting
insulin stays the body for 3 to 5 hours. On the other hand, short acting
analog stays in the body for 6 to 8 hours. Further, premixed analog
insulin is also a form of insulin which is used in diabetes. It is made
by combining rapid acting and long acting insulin in a ratio. However,
in type 2 diabetes patients, sulfonylurea are used. Sulfonylurea
stimulate the insulin production in the pancreas. Moreover, sulfonylurea
help in increasing the amount of insulin which is produced by the
pancreas. Thiazolidinediones is another class of anti diabetic drugs.
Thiazolidinediones reduce insulin resistance in fat and muscles. They
also lower glucose production by the liver. Meglitinide is another class
of anti diabetic drug. Amount of insulin produced by pancreas is
increased with the help of meglitinides. Moreover, GLP-I agonists help
in maintenance of blood sugar in a target range without leading to low
blood sugar or weight gain, whereas alpha glucosidaseinhibitors slow
down the digestion of starch thus maintaining the blood sugar level.
Browse Complete Report:
https://www.crystalmarketresearch.com/report/diabetes-devices-and-drugs-market The major driver for this market is increasing prevalence of
diabetes. According to International Diabetes Federation, in 2015,
diabetes affected 415 million people worldwide and this number is
expected to reach up to 642 million by 2040. Thus, this rapidly rising
diabetic population is set to drive the demand for diabetes devices and
drugs market. Additionally, increase in prevalence of obesity in
geriatric population is set to further drive the market growth. For
instance, as per WHO, in 2014, more than 1.9 billion adults, 18 years
and older, were overweight. Out of these, over 600 million were obese.
Moreover, it states that, in 2014, 41 million children whose age was
under 5 were obese or overweight. Further, increasing trend of unhealthy
diet will contribute to the growth of diabetes devices and drugs market.
However, regulatory framework issues will hamper the growth of diabetic
devices and drug market. The major strategy adopted by the major players
is product launch to gain market share and to gain competitive edge. For
instance, in 2015, Janssen India launched INVOKANA for diabetic
patients. INVOKANA is a sodium glucose co-transporter 2 inhibitor. It
helps adults to achieve adequate control on diabetes who previously were
not able to achieve control on diabetes. Major Market Players: AaAaAeAcy
GlaxoSmithKline PLC Aa Abbott Laboratories AaAaAeAcy Takeda
Pharmaceutical Company Limited AaAaAeAcy AstraZe AaAaAeAcy Johnson &
Johnson Services, Inc. AaAaAeAcy F. Hoffmann La-Roche Ltd. B. Braun
Melsungen AG AaAaAeAcy Bayer AG AaAaAeAcy Becton AaAaAeAcy Dickinson and
C AaAaAeAcy BoehringerIngelheim International GmbH AaAaAeAcy DexCom,
Inc. AaAaAeAcy Eli and Company AaAaAeAcy Lupin Limited AaAaAeAcy Novo
Nordisk A/S AaAaAeAcy Medtronic AaAaAeAcy Merck & Co., Inc.
AaAaAeAcy Novartis AG AaAaAeAcy Sanofi. Request TOC:
https://www.crystalmarketresearch.com/report/diabetes-devices-and-drugs-market#customi Diabetes Devices and Drugs Market Segmentation: By
Devices: Insulin Delivery Devices o Insulin Injectors o Insulin Syringes
o Insulin Pumps o Insulin Pens Diabetes Monitoring and Diagnostic
Devices o Continuous Glucose Monitoring Devices o Analog Glucose Meter o
Lancets and Lancing Devices o Glucose Test Strips o Others By Therapy:
Non-insulin Injectable Anti-diabetes Drugs o GLP-1 Analogs Oral
Anti-diabetes Drugs Class o SGLT-2 Inhibitors o Sulphonylureas o
Thiazolidinediones o DPP-4 Inhibitors o Biguanides o
Alpha-glucosidaseInhibitors o Meglitinides Insulin o Premixed Insulin
Derivatives o Intermediate-acting Insulin Derivatives o Rapid-acting
Insulin Derivatives o Short-acting Insulin Derivatives o Long-acting
Insulin Derivatives By Region: North America o U.S o Canada o Mexico
Europe o Germany o France o UK o Italy o Spain o Rest of Europe
Asia-Pacific o Japan o China o Australia o India o South Korea o Rest of
Asia-Pacific Rest of the World o Brazil o South Africa o Saudi Arabia o
Turkey o United Arab Emirates o Others About Us: Crystal Market Research
is a U.S. based market research and business intelligence company.
Crystal offers one stop solution for market research, business
intelligence, and consulting services to help clients make more informed
decisions. It provides both syndicated as well as customized research
studies for its customers spread across the globe. The company offers
market intelligence reports across a broad range of industries including
healthcare, chemicals & materials, technology, automotive, and
energy. Contact Us: Judy 304 South Jones Blvd, Suite 1896, Las Vegas NV
89107, United States Toll Free: +1-888-213-4282 Email:
sales@crystalmarketresearch.com Blog: blog.crystalmarketresearch.com
Website: www.crystalmarketresearch.com

Copyright [c] 2017 UKPRwire Provided by SyndiGate Media Inc. ( Syn

COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.